// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Early bedside clinical prediction of deterioration in COVID-19 happy hypoxaemic phenotype associated with good prognosis

Athanasios Mamarelis - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Mortality after hospitalisation for COVID19, and identification of prognostic factors on admission that increase mortality risk

Kristian Brooks - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Non-typeable Haemophilus influenzae biofilm formation on air-liquid interface cultured primary human airway epithelia

Katie L Horton - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dex-HEMA

Decreased neutrophil phagocytosis and killing of bacteria in COVID-19 patients

Masoumeh Nomani - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Impact of SARS-CoV-2 heat inactivation on active protease biomarkers in sputum sol

Ciaran Mcgranaghan - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interleukin

Impact of COVID-19 on patients with severe alpha1 antitrypsin deficiency: the IMCA1 study of the EARCO ERS Clinical Research Collaboration, preliminary findings

David G. Parr - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

A single centre observational study of inflammatory biomarkers in Covid 19 and clinically important outcomes

Indrajit Sau - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Severe COVID-19 pneumonia

SJ8903

Capture efficiency of mechanically nebulised synthetic nanoparticles, liposomes, SARS-CoV-2 virus-like particles, and infectious pseudotyped virions is influenced by particle surface charge

John Henderson - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Healthcare utilisation and impact of antifungal stewardships within respiratory care settings: a systematic literature review

Salma Aldossary - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The prevalence and impact of autoantibodies among people with bronchiectasis: a data analysis of the EMBARC registry

Michal Shteinberg - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characterizing Neisseria spp. as novel respiratory pathobionts in bronchiectasis

Micheál Mac Aogáin - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

International BEAT-PCD Consensus Statement for infection prevention and control in Primary Ciliary Dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives

June Kehlet Marthin - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Primary ciliary dyskinesia

N/A

Characteristics and outcomes of adults with primary ciliary dyskinesia (PCD): an EMBARC/BEAT-PCD analysis

Amelia Shoemark - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Primary ciliary dyskinesia

N/A

Home Intravenous Antibiotic Therapy (HIVAT) for adult bronchiectasis patients: safe, efficacious and cost-effective

Hui Min Chen - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The journey to bronchiectasis diagnosis and care: an EMBARC/ELF patient survey

Arietta Spinou - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Bronchiectasis severity assessment tools to predict clinical outcomes in the Indian Bronchiectasis Registry

Raja Dhar - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A experience of using intrapleural fibronolytics in a large district general hospital

Muhammad Bilal Khan Niazi - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Persistent lung abnormalities versus established fibrosis: a prospective study of COVID-19 follow-up

Bavithra Vijayakumar - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Respiratory Physiological Sequelae following Coronavirus Infection: A Systematic Review

Christopher C. Huntley - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Depression, anxiety, traumatic stress and burnout in healthcare workers (HCWs) during the COVID-19 pandemic in Greece:a multi-center, cross-sectional study

Nikolaos Athanasiou - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Depression

N/A

Copyright © 2026. QuantiNova All rights reserved